We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Analysts now expect Eli Lilly’s earnings per share (EPS) to reach $6.77 by Q4 2025, nearly doubling from where it is today. Knowing that stock price performance is mainly driven by EPS growth, this is ...

Morgan Stanley (NYSE:MS) expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic signal of long-term momentum shifting to the upside. This follows a successful ...

This week, Phil Oakley has analysed two shares, DexCom (US:DXCM) and Auto Trader (AUTO), which have decent earnings growth forecasts but rich valuations. It looks like both companies will need ...